JPMorgan Downgrades Bruker (BRKR) to Neutral

Wed, 14 Oct 2026 05:52:37 -0400

JPMorgan analyst Casey Woodring downgraded Bruker (NASDAQ: BRKR) from Overweight to Neutral with a price target of $60.00 (from $42.00).

For an analyst ratings summary and ratings history on Bruker click here. For more ratings news on Bruker click here.

Shares of Bruker closed at $56.19 yesterday.

JPMorgan Downgrades Bruker (BRKR) to Neutral

Wed, 14 Oct 2026 05:52:37 -0400

JPMorgan analyst Casey Woodring downgraded Bruker (NASDAQ: BRKR) from Overweight to Neutral with a price target of $60.00 (from $42.00).

For an analyst ratings summary and ratings history on Bruker click here. For more ratings news on Bruker click here.

Shares of Bruker closed at $56.19 yesterday.

Bruker (BRKR) PT Raised to $62 at TD Cowen

Tue, 13 Oct 2026 09:30:41 -0400

TD Cowen analyst Kyle Boucher raised the price target on Bruker (NASDAQ: BRKR) to $62.00 (from $60.00) while maintaining a rating.

Bruker (BRKR) PT Raised to $70 at Barclays

Wed, 07 Oct 2026 03:49:02 -0400

Barclays analyst Luke Sergott raised the price target on Bruker (NASDAQ: BRKR) to $70.00 (from $58.00) while maintaining a Overweight rating.

Untargeted timsTOF Mass Spectrometry Enables Discovery and Mapping of Draft Atlas of the Human Plasma Proteome at Proteoform Resolution

Tue, 06 Oct 2026 07:00:00 -0400

Charité principal investigator Markus Ralser and colleagues discover and map 179,000 plasma proteoforms, revealing a vast molecular landscape for functional proteomics in biomedical research, drug discovery and biomarker discovery

BERLIN--(BUSINESS WIRE)-- Bruker Corporation (Nasdaq: BRKR) announced a seminal bioRxiv preprint, describing a draft atlas of the human plasma proteome at isoform, or proteoform, resolution. The study was conducted by principal investigator Markus Ralser at Charité – Universitätsmedizin Berlin and collaborators. The preprint “A draft atlas of the human plasma proteome at isoform resolution” was posted on September 28, 2026 at

Untargeted timsTOF Mass Spectrometry Enables Discovery and Mapping of Draft Atlas of the Human Plasma Proteome at Proteoform Resolution

Tue, 06 Oct 2026 07:00:00 -0400

Bruker (BRKR) PT Raised to $72 at Guggenheim

Thu, 01 Oct 2026 08:47:49 -0400

Guggenheim analyst Subbu Nambi raised the price target on Bruker (NASDAQ: BRKR) to $72.00 (from $70.00) while maintaining a Buy rating.

Bruker unveils new proteomics workflows at HUPO 2026

Mon, 28 Sep 2026 07:02:52 -0400

Bruker Corporation (Nasdaq: BRKR) announced several new workflows for its timsUltra AIP and timsOmni mass spectrometry platforms at the Human Proteome Organization World Congress 2026 in Singapore, targeting drug discovery and disease biology research.

A multi-enzyme dia-PASEF method for the timsUltra AIP instrument combined complementary protease digests to yield approximately 350,000 peptides per sample in Parkinson's brain tissue, identifying around 14,500 protein isoforms corresponding to more than 10,000 canonical proteins, according to the company.

Bruker's ProteoScape software now provides a direct path from discovery proteomics to targeted validation using prm-PASEF, allowing researchers to convert discovery results into targeted protein and biomarker assays

Bruker Advances Functional Proteomics with Novel timsUltra AIP and timsOmni Workflows for Drug Discovery & Development and Disease Biology Research

Mon, 28 Sep 2026 07:00:00 -0400

MultiDIA-PASEF significantly increases protein sequence coverage on timsUltra AIP
ProteoScape connects PASEF discovery with rapid prm-PASEF target validation
Spectronaut® AI transfer learning accelerates adaptation to new MS capabilities
Guided PASEF EXciD enables high-throughput glycopeptide characterization
Integrated HDX-MS workflows advance protein conformation and interaction studies
timsOmni™ enables RNA and DNA top-down structural and native RNA analysis

SINGAPORE--(BUSINESS WIRE)-- At the Human Proteome Organization World Congress 2026, Bruker Corporation (Nasdaq: BRKR) today announced unique new timsUltra AIP and timsOmni workflows for deeper protein-sequence coverage, targeted validation, mobility-resolved glycopeptide characterization, structural proteomics, and oligonucleotide analysis. Multi-enzyme dia-PASEF provides additional peptide information

Bruker Advances Functional Proteomics with Novel timsUltra AIP and timsOmni Workflows for Drug Discovery & Development and Disease Biology Research

Mon, 28 Sep 2026 07:00:00 -0400

MultiDIA-PASEF significantly increases protein sequence coverage on timsUltra AIP
ProteoScape connects PASEF discovery with rapid prm-PASEF target validation
Spectronaut® AI transfer learning accelerates adaptation to new MS capabilities
Guided PASEF EXciD enables high-throughput glycopeptide characterization
Integrated HDX-MS workflows advance protein conformation and interaction studies
timsOmni™ enables RNA and DNA top-down structural and native RNA analysis

Bruker wins $6M+ NMR systems order from UC Berkeley

Mon, 21 Sep 2026 07:02:14 -0400

Bruker Corporation (Nasdaq: BRKR) has received a multi-system order from the University of California, Berkeley, valued at more than $6 million, for high-field Nuclear Magnetic Resonance (NMR) instrumentation at the Pines Magnetic Resonance Center (PMRC). Delivery is expected in 2027.

The order centers on a Bruker AV NEO-X 800 MHz spectrometer equipped with a cryogenically cooled MAS CryoProbe, along with several additional NMR systems and upgrades supporting solid-state, solution-state, and Dynamic Nuclear Polarization (DNP) research.

The PMRC is a shared NMR facility that provides around-the-clock access to researchers from academia, national laboratories, and industry. The new instrumentation will support research in chemistry,

Bruker Receives Order for High-Field NMR Systems for Major Upgrade of Magnetic Resonance Research Infrastructure at UC Berkeley

Mon, 21 Sep 2026 07:00:00 -0400

New high-field NMR instrumentation strengthens biomolecular and materials science research at the UC Berkeley Pines Magnetic Resonance Center

BERKELEY, Calif.--(BUSINESS WIRE)-- Bruker Corporation (Nasdaq: BRKR) today announced a multi-system order from the University of California, Berkeley for high-field Nuclear Magnetic Resonance (NMR) instrumentation at the Pines Magnetic Resonance Center. The investment will enhance access to next-generation NMR technologies, including 800 MHz–class instrumentation. These capabilities strengthen research in chemistry, materials science, structural biology, and related fields across UC Berkeley and Lawrence Berkeley National Laboratory.

This press release features multimedia. View

Bruker Receives Order for High-Field NMR Systems for Major Upgrade of Magnetic Resonance Research Infrastructure at UC Berkeley

Mon, 21 Sep 2026 07:00:00 -0400

New high-field NMR instrumentation strengthens biomolecular and materials science research at the UC Berkeley Pines Magnetic Resonance Center

This press release features multimedia. View

Form 4 BRUKER CORP For: Sep 15 Filed by: Munch Mark

Wed, 16 Sep 2026 16:15:00 -0400

si-local-file:///var/storage/secattach/20260916/27070450.html

Form 144 BRUKER CORP Filed by: Munch Mark

Tue, 15 Sep 2026 16:19:00 -0400

si-local-file:///var/storage/secattach/20260915/27065116.html

UBS Starts Bruker (BRKR) at Neutral

Wed, 09 Sep 2026 06:07:25 -0400

UBS analyst Douglas Schenkel initiates coverage on Bruker (NASDAQ: BRKR) with a Neutral rating and a price target of $65.00.

For an analyst ratings summary and ratings history on Bruker click here. For more ratings news on Bruker click here.

Shares of Bruker closed at $58.37 yesterday.

Form 4 BRUKER CORP For: Aug 15 Filed by: Herman Gerald N